Evidence map›Paper›PMID 38125888›Full record

ArticleFrontiers in pharmacology2023

Lydia Bisbal Lopez, Domenico Ravazza, Matilde Bocci, Aureliano Zana, Lucrezia Principi, Sheila Dakhel Plaza, Andrea Galbiati, Ettore Gilardoni, Jörg Scheuermann, Dario Neri and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lydia Bisbal LopezChemistry Department, Università degli Studi di Milano, Milano, Italy.
Domenico RavazzaR&D Department, Philochem AG, Otelfingen, Switzerland.
Matilde BocciR&D Department, Philochem AG, Otelfingen, Switzerland.
Aureliano ZanaR&D Department, Philochem AG, Otelfingen, Switzerland.
Lucrezia PrincipiR&D Department, Philochem AG, Otelfingen, Switzerland.
Sheila Dakhel PlazaR&D Department, Philochem AG, Otelfingen, Switzerland.
Andrea GalbiatiR&D Department, Philochem AG, Otelfingen, Switzerland.
Ettore GilardoniR&D Department, Philochem AG, Otelfingen, Switzerland.
Jörg ScheuermannDepartment of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zürich, Switzerland.
Dario NeriR&D Department, Philochem AG, Otelfingen, Switzerland.
Luca PignataroChemistry Department, Università degli Studi di Milano, Milano, Italy.
Cesare GennariChemistry Department, Università degli Studi di Milano, Milano, Italy.
Samuele CazzamalliR&D Department, Philochem AG, Otelfingen, Switzerland.
Alberto Dal CorsoChemistry Department, Università degli Studi di Milano, Milano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune-stimulating antibody conjugates (ISACs) equipped with imidazoquinoline (IMD) payloads can stimulate endogenous immune cells to kill cancer cells, ultimately inducing long-lasting anticancer effects. A novel ISAC was designed, featuring the IMD Resiquimod (R848), a tumor-targeting antibody specific for Carbonic Anhydrase IX (CAIX) and the protease-cleavable Val-Cit-PABC linker.

Indexed as

immune stimulating antibody conjugatesprodrugsquantitative biodistributionResiquimodtoll-like receptors

Identifiers

PMID38125888
PMCPMC10731371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.